Capacity Expansion through Investment and Innovation
We have made considerable investments in scale capacities to satisfy the needs of our customers from early stage development to commercial production.
Considering the continuous growth and evolution of the Peptide therapeutic market, the strategy of the PolyPeptide Group is to anticipate the market needs and to extend its available capacities. Our strategy is to invest in new manufacturing capacities and constantly improve the productivity of our assets through the deployment of innovative, cost-efficient and sustainable technology solutions.
In recent years, we have made considerable investment in small, medium and large scale capacities to satisfy the needs of our customers from early stage to commercial productions.
In regard to the technology, we have implemented our latest innovative and “state of the art” features at all of our sites that includes, but is not limited to, mechanical design, online monitoring and full automation.
An illustration of this approach is our SPPS 600L reactor recently installed in Braine-L’Alleud, Belgium. Our optimized design provides multiple benefits including:
- The significant reduction of solvent consumption during the post-coupling and post-deprotection washing steps (up to 70% reduced consumption of DMF observed)
- A substantial improvement in operational time through the automation of the different process steps
- Scale up or a transfer mastered by similar design at different scales
- Improvements in the reproducibility and product quality through enhanced process monitoring at critical steps
